Negative effect of hepatitis in overall and progression-free survival among patients with diffuse large B-cell lymphoma.

about

Negative effect of hepatitis in overall and progression-free survival among patients with diffuse large B-cell lymphoma.

Item

http://www.wikidata.org/entity/Q55479805

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Negative effect of hepatitis i ...... diffuse large B-cell lymphoma.

@en

Negative effect of hepatitis i ...... diffuse large B-cell lymphoma.

@nl

type

Item

label

Negative effect of hepatitis i ...... diffuse large B-cell lymphoma.

@en

Negative effect of hepatitis i ...... diffuse large B-cell lymphoma.

@nl

prefLabel

Negative effect of hepatitis i ...... diffuse large B-cell lymphoma.

@en

Negative effect of hepatitis i ...... diffuse large B-cell lymphoma.

@nl

P1476

Negative effect of hepatitis i ...... diffuse large B-cell lymphoma.

@en

P2093

Abdullah A Alesa

http://www.w3.org/2001/XMLSchema#string

Mubarak M Al-Mansour

http://www.w3.org/2001/XMLSchema#string

Muhammad A Khan

http://www.w3.org/2001/XMLSchema#string

Musab A Alsubaie

http://www.w3.org/2001/XMLSchema#string

Saif A Alghamdi

http://www.w3.org/2001/XMLSchema#string

P2860

Natural history of hepatitis B virus infection: an update for clinicians.

Evaluation of survival data and two new rank order statistics arising in its consideration.

Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports

Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients.

Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy

The impact of hepatitis B virus (HBV) infection on clinical outcomes of patients with diffuse large B-cell lymphoma.

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.

Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.

Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.

P2888

s13027-018-0190-9

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13027-018-0190-9

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-06-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1104460028

http://www.w3.org/2001/XMLSchema#string

P698

29977329

http://www.w3.org/2001/XMLSchema#string

P932

5992760

http://www.w3.org/2001/XMLSchema#string